This Huge Win Could Boost Novavax's Fortunes -- and It Has Nothing to Do With COVID-19

Since early 2020, Novavax (NASDAQ:NVAX) has received a lot of attention due to its efforts to develop a COVID-19 vaccine. That attention is deserved. The biotech's COVID-19 vaccine candidate NVX-CoV2373 appears to be quite promising.

Novavax has been at the center of attention more recently for great results announced last week from a clinical study of a different vaccine. This huge win could boost Novavax's fortunes -- and it has nothing to do with COVID-19.